RxDoctor Payments Data

Dale Kresge, MD

Internal Medicine · Dallastown, PANPI 1083685176

Payments from drug & device makers

$9,090in general payments, 2019–2025

Across 577 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$979
  • AbbVie$943
  • Pfizer$789
  • AstraZeneca$709
  • Lilly USA, LLC$647
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$9,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK78$1,151
Novo Nordisk69$979
AbbVie(2 entities)53$943
Pfizer79$789
AstraZeneca43$709
Lilly USA, LLC39$647
Johnson & Johnson19$323
Amarin Pharma, Inc.15$288
Boehringer Ingelheim18$268
Amgen16$265
Merck17$248
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$207
Astellas Pharma US Inc9$193
Abbott9$166
Novartis8$129
E.r. Squibb & Sons, L.L.C.6$107
Teva Pharmaceuticals USA, Inc.6$107
Shield Therapeutics Inc2$103
Exact Sciences4$86
Sanofi-aventis U.S. LLC6$84
Esperion Therapeutics, Inc.5$78
Biofire Diagnostics, LLC2$75
Phathom Pharmaceuticals, Inc.3$72
Biohaven Pharmaceutical Holding Company Ltd.3$70
Aimmune Therapeutics, Inc.3$65
Otsuka America Pharmaceutical, Inc.3$58
Sanofi Pasteur Inc.3$52
Lundbeck LLC3$51
Axsome Therapeutics, Inc.2$48
Seqirus USA Inc2$46
Jazz Pharmaceuticals Inc.3$44
Dexcom, Inc.3$41
IBSA Pharma Inc.2$38
Biohaven Pharmaceuticals, Inc.2$37
Kaleo, Inc.2$37
Avanir Pharmaceuticals, Inc.2$36
Harmony Biosciences LLC2$34
Cequr Corporation2$32
Xeris Pharmaceuticals, Inc.2$31
Kowa Pharmaceuticals America, Inc.2$27
Eisai Inc.2$26
Takeda Pharmaceuticals U.S.A., Inc.1$24
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$24
Sunovion Pharmaceuticals Inc.1$24
Tactile Systems Technology Inc1$23
Adlon Therapeutics L.p.1$23
Actelion Pharmaceuticals US, Inc.1$22
Medicomp Inc1$19
Viatris Specialty LLC1$19
Ironshore Pharmaceuticals Inc.1$19
Radius Health, Inc.1$19
Optinose US, Inc.1$16
Teleflex LLC1$15
Genentech USA, Inc.1$15
Inspire Medical Systems, Inc.1$14
Corcept Therapeutics1$14
Nestle Healthcare Nutrition Inc.1$12

How this compares

$9,090 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$444,855
Medicare patients
486
Services billed
15,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$247,623
JardianceEmpagliflozin170$239,867
EliquisApixaban194$218,230
MounjaroTirzepatide61$85,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$68,782
Breo ElliptaFluticasone/Vilanterol82$49,571
CreonLipase/Protease/Amylase21$48,529
TradjentaLinagliptin40$47,996
TrulicityDulaglutide33$39,858
XareltoRivaroxaban35$33,376
JanuviaSitagliptin Phosphate23$32,915
FarxigaDapagliflozin Propanediol21$25,557
Spiriva RespimatTiotropium Bromide28$19,376
Tresiba Flextouch U-200Insulin Degludec13$15,367
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$13,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto$268$318,535255 claims
Novo NordiskOzempic$979$247,623164 claims
PfizerEliquis$789$218,230194 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$1,151$142,735253 claims
Lilly USA, LLCMounjaro, Trulicity$647$125,03794 claims
AbbVieCreon, Synthroid$943$52,807108 claims
Johnson & JohnsonXarelto$323$33,37635 claims
MerckJanuvia$248$32,91523 claims
AstraZenecaFarxiga$709$25,55721 claims
Esperion Therapeutics, Inc.Nexletol$78$8,31712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Dallastown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →